Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell response enhancement via MHC class II invariant chain-adjuvanted antigen presentation
- Molecular classification
- Adjuvant, MHC class II associated invariant chain (Ii), CD74, Type II membrane glycoprotein
01
Overview
This target refers to the strategy of enhancing T cell immune responses by fusing antigens to the major histocompatibility complex (MHC) class II-associated invariant chain (Ii, also known as CD74). This approach is used in vaccine design and immunotherapy to improve antigen presentation and stimulate robust T cell responses by increasing delivery of the antigen to MHCII loading compartments.
- Other names
- Ii-adjuvanted antigen presentationCD74-adjuvanted antigen presentationMHC class II invariant chain-based vaccine adjuvantIi fusion vaccine strategy
02
Mechanism of action
Genetic fusion of antigen to MHC class II invariant chain (Ii) enhances antigen processing and presentation on both MHC class I and MHC class II molecules, leading to increased T cell activation and a robust immune response.
03
Biological functions
Antigen presentationT cell activationImmune response enhancementChaperone for MHC class II moleculesDirecting MHC class II to endosomal compartmentsPreventing premature peptide binding to MHC class II
04
Disease associations
Infectious Diseases (vaccine target)Cancer (immunotherapy target)
05
Safety considerations
Potential for off-target effectsEnsuring no significant anti-invariant chain immunogenicity
Beyond the preview
Go deeper on T cell response enhancement via MHC class II invariant chain-adjuvanted antigen presentation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T cell response enhancement via MHC class II invariant chain-adjuvanted antigen presentation.